
AttackMS is a trial by ProfK that offers the individual the chance to get on natalizumab rapidly after entry into the health care system with the opportunity to receive natalizumab whilst the diagnostic work-up occurs and then to either stop treatment – if the diagnosis of CIS or MS is not confirmed – or continue taking natalizumab as a first line treatment, or switch to an...